荣昌生物
(688331)
| 流通市值：89.96亿 | | | 总市值：302.38亿 |
| 流通股本：1.62亿 | | | 总股本：5.44亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 330,434,802.62 | 1,082,953,432.23 | 769,470,314.65 | 422,427,546.05 |
| 营业收入 | 330,434,802.62 | 1,082,953,432.23 | 769,470,314.65 | 422,427,546.05 |
| 二、营业总成本 | 682,453,542.19 | 2,632,979,340.34 | 1,819,967,398.27 | 1,142,212,436.67 |
| 营业成本 | 74,359,654.52 | 244,398,781.48 | 177,798,986.36 | 95,381,370.12 |
| 税金及附加 | 4,438,577.93 | 8,230,401.26 | 5,878,516.91 | 3,572,508.69 |
| 销售费用 | 187,504,942.42 | 775,186,042.71 | 539,790,867.31 | 350,167,541.04 |
| 管理费用 | 74,259,896 | 304,226,803.85 | 242,865,841.79 | 163,924,256.74 |
| 研发费用 | 331,178,800.01 | 1,306,306,793.92 | 857,977,852.4 | 540,452,903.93 |
| 财务费用 | 10,711,671.31 | -5,369,482.88 | -4,344,666.5 | -11,286,143.85 |
| 其中:利息费用 | 12,859,889.2 | 23,090,997.63 | 13,656,827.51 | 5,997,323.63 |
| 其中:利息收入 | 3,373,492.81 | 28,143,223.16 | 19,054,230.73 | 15,127,463.89 |
| 加:公允价值变动收益 | -49,464.61 | - | 5,169,310.95 | 3,836,310.95 |
| 加:投资收益 | 45,340.29 | 6,975,280.93 | 1,473,364.03 | 1,114,554.89 |
| 资产处置收益 | - | 4,171.21 | - | - |
| 资产减值损失(新) | - | -12,875,650.04 | -8,671,903.11 | -8,671,903.11 |
| 信用减值损失(新) | -4,658,663.1 | -11,275,815.26 | -6,247,338.71 | -4,108,484.94 |
| 其他收益 | 11,732,665.41 | 65,669,037.94 | 33,966,289.8 | 28,255,417.27 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -344,948,861.58 | -1,501,528,883.33 | -1,024,807,360.66 | -699,358,995.56 |
| 加:营业外收入 | 68,680.78 | 85,259.21 | 71,134.69 | 57,594.98 |
| 减:营业外支出 | 4,041,515.69 | 9,785,552.58 | 5,849,633.63 | 4,059,396.61 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -348,921,696.49 | -1,511,229,176.7 | -1,030,585,859.6 | -703,360,797.19 |
| 六、净利润 | -348,921,696.49 | -1,511,229,176.7 | -1,030,585,859.6 | -703,360,797.19 |
| 持续经营净利润 | -348,921,696.49 | -1,511,229,176.7 | -1,030,585,859.6 | -703,360,797.19 |
| 归属于母公司股东的净利润 | -348,921,696.49 | -1,511,229,176.7 | -1,030,585,859.6 | -703,360,797.19 |
| (一)基本每股收益 | -0.65 | -2.8 | -1.91 | -1.3 |
| (二)稀释每股收益 | -0.65 | -2.8 | -1.91 | -1.3 |
| 八、其他综合收益 | -23,282,589.1 | -58,917,976.2 | -7,908,770.96 | -5,662,982.02 |
| 归属于母公司股东的其他综合收益 | -23,282,589.1 | -58,917,976.2 | -7,908,770.96 | -5,662,982.02 |
| 九、综合收益总额 | -372,204,285.59 | -1,570,147,152.9 | -1,038,494,630.57 | -709,023,779.21 |
| 归属于母公司股东的综合收益总额 | -372,204,285.59 | -1,570,147,152.9 | -1,038,494,630.57 | -709,023,779.21 |
| 公告日期 | 2024-04-27 | 2024-03-28 | 2023-10-31 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |